Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

NCT03386071 | Unknown

• 2 other identifiers: 17-001886Compassionate Use Trametinib
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The dosage of trametinib for oral administration is 2mg once daily. The patient is instructed to take the trametinib oncedaily dose at approximately the same time each day, by mouth with approximately 200 mL (almost 1 cup) of water on an empty stomach, either 1 hour before or 2 hours after a meal.

Conditions

Progressive Metastatic Castrate Resistant Prostate Cancer

Interventions

Trametinib 2 mg DRUG

The dosage of trametinib for oral administration is 2mg once daily.

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Prostate
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Progressive Metastatic Castrate Resistant Prostate Cancer

You may not qualify if:

• Absence of Progressive Metastatic Castrate Resistant Prostate Cancer

Sponsors & Collaborators

• Jonsson Comprehensive Cancer Center: lead
• Novartis: collaborator

MeSH Terms

Interventions

trametinib

Study Officials

• Matthew Rettig, M.D.

  Jonsson Comprehensieve Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: expanded access
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 21, 2017
• First Posted: December 29, 2017
• Last Updated: January 16, 2019

Record last verified: 2019-01